Correlation Between Visa and Akari Therapeutics

Can any of the company-specific risk be diversified away by investing in both Visa and Akari Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Visa and Akari Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Visa Class A and Akari Therapeutics PLC, you can compare the effects of market volatilities on Visa and Akari Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Visa with a short position of Akari Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Visa and Akari Therapeutics.

Diversification Opportunities for Visa and Akari Therapeutics

-0.76

Correlation Coefficient

Visa  Akari Therapeutics

Pay attention - limited upside

The 3 months correlation between Visa and Akari is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Visa Class A and Akari Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akari Therapeutics PLC and Visa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Visa Class A are associated (or correlated) with Akari Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akari Therapeutics PLC has no effect on the direction of Visa i.e., Visa and Akari Therapeutics go up and down completely randomly.

Pair Corralation between Visa and Akari Therapeutics

Taking into account the 90-day investment horizon Visa Class A is expected to generate 0.17 times more return on investment than Akari Therapeutics. However, Visa Class A is 6.02 times less risky than Akari Therapeutics. It trades about 0.08 of its potential returns per unit of risk. Akari Therapeutics PLC is currently generating about -0.04 per unit of risk. If you would invest  21,128  in Visa Class A on September 1, 2024 and sell it today you would earn a total of  10,380  from holding Visa Class A or generate 49.13% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	99.8%
Values	Daily Returns

Visa Class A  vs.  Akari Therapeutics PLC

Visa Class A

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Visa Class A are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Visa showed solid returns over the last few months and may actually be approaching a breakup point.

Akari Therapeutics PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Akari Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Visa and Akari Therapeutics

The main advantage of trading using opposite Visa and Akari Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Visa position performs unexpectedly, Akari Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will offset losses from the drop in Akari Therapeutics' long position.

The idea behind Visa Class A and Akari Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.